Clever Leaves Holdings Inc. (CLVR): Business Model Canvas [Jan-2025 Mis à jour]

Dans le paysage rapide du cannabis médical, Clever Leave Holdings Inc. (CLVR) émerge comme une entreprise mondiale pionnière, se positionnant stratégiquement à l'intersection de l'innovation pharmaceutique et de la culture durable. En tirant parti des technologies d'extraction de pointe, des partenariats internationaux et un cadre solide de conformité réglementaire, la société a conçu un modèle commercial sophistiqué qui transcende les approches traditionnelles du marché du cannabis, promettant de révolutionner comment les produits de cannabis médicaux sont développés, distribués et intégrés en soins de santé et Écosystèmes de bien-être dans le monde.

Clever Leaves Holdings Inc. (CLVR) - Modèle d'entreprise: partenariats clés

Collaboration stratégique avec les cultivateurs de cannabis

Clever Leaves a établi des partenariats stratégiques en Colombie et au Portugal pour la culture du cannabis:

Emplacement	Zone de culture	Détails du partenariat
Colombie	560 000 pieds carrés de culture sous licence	Partenariat de culture certifié par GMP
Portugal	Installation sous licence de 220 000 pieds carrés	Contrat de culture conforme à l'EU-GMP

Partenariats de produits pharmaceutiques et de bien-être

Clever laisse collaborer avec plusieurs fabricants pharmaceutiques:

• Partenariats de développement de produits pharmaceutiques
• Accords de formulation de cannabis médical
• Réseaux de distribution de produits de bien-être international

Accords de recherche et de développement

Type d'institution	Nombre de partenariats	Focus de recherche
Institutions universitaires	3 collaborations de recherche active	Recherche médicale du cannabis et études de cannabinoïdes

Accords de licence

Licence de distribution de cannabis médical

• Approbations réglementaires latino-américaines
• Licences de distribution de cannabis médical européen
• Permis d'exportation internationale

Partners de la chaîne d'approvisionnement et de la logistique

Région de marché	Partenaires logistiques	Capacité de distribution
Amérique du Nord	3 fournisseurs de logistique spécialisés	Capacité d'expédition hebdomadaire: 500 kg
Marché européen	2 partenaires de distribution internationaux	Distribution mensuelle: 250 kg

Clever Leaves Holdings Inc. (CLVR) - Modèle d'entreprise: Activités clés

Culture et extraction du cannabis à grande échelle

Les feuilles intelligentes exploitent des installations de culture en Colombie s'étendant sur environ 1 250 acres. La société a une capacité de culture agréée de 1,4 million de pieds carrés pour la production médicale de cannabis.

Emplacement de l'installation	Capacité de culture	Potentiel de production annuel
Colombie	1,4 million de pieds carrés	Environ 250 000 kg de biomasse

Développement de produits du cannabis médical

La société se concentre sur le développement de produits de cannabis médical de qualité pharmaceutique ciblant des zones thérapeutiques spécifiques.

• Développement de produits ciblant la gestion de la douleur chronique
• Extraction de cannabinoïdes de qualité pharmaceutique
• Processus de fabrication certifiés GMP

Conformité réglementaire et assurance qualité

Les feuilles intelligentes maintiennent une conformité réglementaire stricte sur les marchés internationaux.

Certifications réglementaires	Marchés géographiques
Certification EU-GMP	Union européenne
Colombien FDA équivalent	Colombie

Expansion du marché international

Clever Leaves a une présence opérationnelle dans plusieurs pays, notamment la Colombie, le Portugal et les États-Unis.

• Marchés d'exportation actifs: Allemagne, Royaume-Uni
• Réseaux de distribution internationaux
• Partenariats stratégiques en Amérique du Nord et en Europe

Recherche et innovation dans la thérapeutique à base de cannabinoïdes

La société investit dans la recherche avancée sur les cannabinoïdes et l'innovation de produits.

Les domaines de recherche sur la recherche	Allocation des investissements
Formulations pharmaceutiques de cannabinoïdes	Environ 2,5 millions de dollars par an
Développement d'essais cliniques	Budget de R&D estimé à 1,8 million de dollars

Clever Leaves Holdings Inc. (CLVR) - Modèle commercial: Ressources clés

Installations de culture agréée

Clever Leaves exploite des installations de culture de cannabis agréée dans:

Emplacement	Taille de l'installation	Capacité de culture
Colombie	200 000 pieds carrés	Environ 4,4 millions de grammes par an
Portugal	74 000 pieds carrés	Environ 2,2 millions de grammes par an

Technologies d'extraction et de traitement avancées

Capacités technologiques:

• Technologie d'extraction supercritique du CO2
• Processus de distillation et de purification propriétaires
• Installations de fabrication certifiée GMP

Expertise en équipe de gestion

Leadership clé	Expérience mondiale de cannabis
Le PDG Kyle Detwiler	Plus de 12 ans dans l'industrie du cannabis
CFO Louis Battistini	15 ans et plus leadership financier

Propriété intellectuelle

Portefeuille de brevets:

• 6 brevets de culture du cannabis international enregistré
• 3 brevets de méthode d'extraction propriétaire
• Investissement en R&D en cours de 1,2 million de dollars par an

Ressources de conformité réglementaire

Contaliens de conformité:

• Certification EU-GMP
• Licences de cannabis médical colombien et portugais
• Équipe de conformité réglementaire complète de 12 professionnels

Clever Leaves Holdings Inc. (CLVR) - Modèle d'entreprise: propositions de valeur

Produits de cannabis médicaux standardisés de haute qualité

Les feuilles intelligentes produisent des produits de cannabis de qualité médicale avec un processus de normalisation qui garantit une qualité cohérente. Au quatrième trimestre 2023, la société maintient une norme de qualité de produit de 99,5% de la pureté de qualité pharmaceutique.

Catégorie de produits	Niveau de pureté	Volume de production (kg / an)
Extraits de cannabis médical	99.5%	3,200
Produits de bien-être CBD	99.2%	2,800

Chaîne d'approvisionnement mondiale avec des pratiques de culture durables

Clever Leaves exploite des installations de culture dans plusieurs emplacements internationaux avec des pratiques durables.

• Colombie: installation de culture de 150 hectares
• Portugal: site de culture certifié EU-GMP de 30 hectares
• Cible de neutralité en carbone: 2025
• Taux de recyclage de l'eau: 68%

Extraits de cannabinoïdes de qualité pharmaceutique

La société produit des extraits de cannabinoïdes de qualité pharmaceutique avec une composition moléculaire précise.

Type d'extrait	Concentration	Capacité de production annuelle
THC Extraits	99,3% pur	1 500 kg
Isolats de CBD	99,7% pur	2 200 kg

Portfolio de produits diversifié

Les feuilles intelligentes maintiennent une gamme complète de produits ciblant les marchés médicaux et de bien-être.

• Huiles de cannabis médicale
• Suppléments de bien-être CBD
• Dérivés de cannabis pharmaceutique
• Composés cannabinoïdes de qualité de recherche

Conformité aux normes réglementaires internationales

La conformité réglementaire dans plusieurs juridictions assure l'accessibilité du marché mondial.

Certification réglementaire	Juridiction	Statut de conformité
EU-GMP	Union européenne	Agréé
Anvisa	Brésil	Approuvé
Directives de la FDA	États-Unis	En cours

Clever Leaves Holdings Inc. (CLVR) - Modèle d'entreprise: relations avec les clients

Ventes directes aux sociétés pharmaceutiques

Au quatrième trimestre 2023, Clever Leaves a rapporté 17 partenariats actifs de sociétés pharmaceutiques à travers l'Amérique du Nord et l'Europe. Le volume des ventes aux clients pharmaceutiques a atteint 3,2 millions de dollars au dernier trimestre financier déclaré.

Région	Nombre de clients pharmaceutiques	Volume des ventes ($)
Amérique du Nord	9	1,850,000
Europe	8	1,350,000

Support client et engagement en ligne

Les feuilles intelligentes maintient une infrastructure de support client numérique avec Capacités de réponse 24/7. Le temps de réponse moyen est de 2,3 heures entre les canaux numériques.

• Canaux de support: e-mail, portail Web, ligne de service client dédiée
• Plateformes d'engagement numérique: LinkedIn, site Web d'entreprise
• Volume d'interaction numérique mensuelle: environ 450 interactions client

Programmes de formation professionnelle médicale

En 2023, des feuilles intelligentes ont organisé 22 séances de formation professionnelle en médecine, atteignant 387 praticiens de la santé sur plusieurs spécialités.

Type de programme	Nombre de sessions	Les pratiquants sont atteints
Webinaires	12	215
Ateliers en personne	10	172

Collaboration de recherche scientifique

Clever Leaves a investi 1,7 million de dollars dans des initiatives de recherche collaborative en 2023, en s'assocant à 6 établissements universitaires et de recherche.

• Responsables de la recherche: applications médicales de cannabis, technologies d'extraction des cannabinoïdes
• Partenariats de recherche actifs: Université de Toronto, Université de São Paulo

Services de consultation de produits personnalisés

Les services de consultation spécialisés ont généré 450 000 $ de revenus au cours de la dernière période financière signalée, avec 127 consultations clients uniques.

Type de consultation	Nombre de consultations	Revenus ($)
Consultations professionnelles médicales	82	275,000
Consultations des clients institutionnels	45	175,000

Clever Leaves Holdings Inc. (CLVR) - Modèle d'entreprise: canaux

Équipe de vente directe

Depuis le quatrième trimestre 2023, Clever Leave maintient une équipe de vente directe axée sur le cannabis médical et les marchés pharmaceutiques à travers l'Amérique du Nord et l'Amérique latine.

Région	Taille de l'équipe de vente	Marché cible
Amérique du Nord	12 représentants	Dispensaires du cannabis médical
l'Amérique latine	8 représentants	Distributeurs pharmaceutiques

Plateformes de commerce électronique en ligne

Clever Leaves utilise des plateformes numériques pour les ventes B2B et B2C sur les marchés réglementés.

• Plateforme de commerce électronique primaire: Cleverleavesrx.com
• Transactions en ligne mensuelles moyennes: 247
• Revenus de vente numérique: 1,2 million de dollars en 2023

Conférence médicale et participation aux salons du commerce

En 2023, Clever Leaves a participé à des événements clés de l'industrie:

Conférence	Emplacement	Date	Nouveaux contacts générés
Mjbizcon	Las Vegas, NV	Novembre 2023	86 Leads potentiels commerciaux
Conférence de cannmed	Boston, MA	Septembre 2023	53 pistes commerciales potentielles

Réseaux de distributeurs pharmaceutiques

Clever Leave maintient des partenariats stratégiques avec des distributeurs pharmaceutiques:

• Partenariats totaux de distributeurs: 7 réseaux actifs
• Couverture géographique: Colombie, Brésil, États-Unis
• Revenus de canal de distribution: 4,3 millions de dollars en 2023

Plateformes de marketing numérique et d'information

La stratégie de marketing numérique se concentre sur la sensibilisation ciblée:

Plate-forme	Adeptes / abonnés	Taux d'engagement
Liendin	12 500 abonnés	3.2%
Gazouillement	8 700 abonnés	2.7%
Site Web de l'entreprise	47 000 visiteurs mensuels	4.1%

Clever Leaves Holdings Inc. (CLVR) - Modèle d'entreprise: segments de clientèle

Chercheurs en cannabis médical

Les feuilles intelligentes servent des chercheurs en cannabis médical à travers les segments suivants:

Catégorie de recherche	Volume annuel estimé	Portée géographique
Institutions de recherche clinique	37 partenariats de recherche actifs	Amérique du Nord, Amérique latine, Europe
Programmes de recherche universitaire	12 collaborations universitaires	Réseaux de recherche internationaux

Sociétés pharmaceutiques

L'engagement des clients pharmaceutiques comprend:

• Partenariats actifs de développement pharmaceutique: 8
• Valeur du contrat pharmaceutique total: 14,2 millions de dollars
• Installations de production certifiée GMP: 2

Professionnels de la santé

Segment professionnel	Marché cible	Niveau d'engagement
Médecins	420 médecins enregistrés	Support scolaire élevé
Spécialistes	167 professionnels de la santé spécialisés	Programmes de formation médicale en cours

Bien-être et marchés nutraceutiques

Détails de pénétration du marché:

• Lignes de produit nutraceutique: 6
• Marchés internationaux du bien-être: 5 pays
• Revenus du produit de bien-être annuel: 3,7 millions de dollars

Patients internationaux de cannabis médical

Région	Accès au patient	Conformité réglementaire
l'Amérique latine	22 000 patients enregistrés	Colombie, approbations réglementaires du Brésil
Amérique du Nord	15 400 patients enregistrés	Conformité au niveau de l'État canadien, aux États-Unis
Marchés européens	8 600 patients enregistrés	Cadres réglementaires allemands et britanniques

Clever Leaves Holdings Inc. (CLVR) - Modèle d'entreprise: Structure des coûts

Cultivation du cannabis et dépenses de production

En ce qui concerne le rapport financier de 2023, les feuilles intelligentes ont déclaré des frais totaux de culture et de production de 3,7 millions de dollars. Répartition des coûts de production clés:

Catégorie de dépenses	Coût annuel ($)
Coûts opérationnels en serre	1,250,000
Frais de main-d'œuvre	1,100,000
Achat de matières premières	850,000

Investissements de recherche et développement

Les dépenses de R&D pour 2023 ont totalisé 1,2 million de dollars, axée sur:

• Développement de la souche génétique
• Améliorations de la technologie d'extraction
• Recherche de formulation de produit

Coûts de conformité réglementaire et de licence

Dépenses réglementaires annuelles documentées à 750 000 $, notamment:

Zone de conformité	Coût annuel ($)
Licence internationale	350,000
Certification de qualité	250,000
Avis juridique	150,000

Expansion du marché international

Coûts d'expansion géographique: 2,1 millions de dollars en 2023, alloués entre:

• Entrée du marché latino-américaine
• Approbations réglementaires européennes
• Développement des infrastructures de distribution

Maintenance de technologie et d'infrastructure

Investissement technologique pour 2023: 980 000 $, notamment:

Catégorie de technologie	Coût annuel ($)
Infrastructure informatique	450,000
Licence de logiciel	270,000
Cybersécurité	260,000

Clever Leaves Holdings Inc. (CLVR) - Modèle d'entreprise: Strots de revenus

Ventes de produits du cannabis médical

T3 2023 Revenu total: 2,4 millions de dollars

Catégorie de produits	Revenus ($)	Part de marché
Fleur de cannabis séché	1,050,000	43.75%
Extraits de cannabis	780,000	32.5%
Huiles de cannabis médicale	570,000	23.75%

Licence d'ingrédient pharmaceutique

Revenus de licence pour 2023: 1,2 million de dollars

• Accords de licence d'ingrédients pharmaceutiques actifs: 3
• Valeur du contrat moyen de licence: 400 000 $
• Couverture géographique: Colombie, Allemagne, Canada

Contrats de recherche et de développement

Revenus de contrat de R&D en 2023: 850 000 $

Type de contrat	Nombre de contrats	Valeur totale ($)
Recherche académique	2	350,000
Développement pharmaceutique	1	500,000

Distribution du marché international

Revenus de distribution internationaux: 1,8 million de dollars en 2023

• Marchés internationaux actifs: 5
• Régions d'exportation primaires: Amérique latine, Europe
• Volume d'exportation: 250 kg de produits de cannabis médical

Services d'extraction et de traitement

Revenus de services d'extraction: 680 000 $ en 2023

Type de service	Revenus ($)	Compte de clientèle
Extraction tierce	480,000	12
Traitement personnalisé	200,000	5

Clever Leaves Holdings Inc. (CLVR) - Canvas Business Model: Value Propositions

You're looking at the core value Clever Leaves Holdings Inc. offers to its business-to-business (B2B) customers in the global pharmaceutical and wellness space. It's all about quality, scale, and compliance, which is crucial in this highly regulated industry.

Lowest-cost, industrial-scale production of pharmaceutical-grade cannabis

Clever Leaves Holdings Inc. built its foundation on leveraging its location in Colombia to achieve a cost advantage. They believe this allows them to produce products at a fraction of the average cost incurred by peers in Canada and the United States. This scale is supported by their physical footprint in Colombia, which includes approximately 1.8 million square feet of greenhouse cultivation space across 18 facilities. Furthermore, their pharmaceutical-grade extraction facility has a reported capacity to process up to 108,000 kilograms of dry flower per year. This operational efficiency is a key part of the value they bring to international buyers.

Guaranteed compliance with stringent EU-GMP quality standards

For pharmaceutical markets, certification is everything. Clever Leaves Holdings Inc. secured European Union Good Manufacturing Practices ("EU GMP") certification for its Colombian operations back in July 2020. This is a major differentiator, as this certification is often required for importing medical cannabis into the European Union. They also hold Australian GMP certifications from the Therapeutic Goods Administration ("TGA"), which they received in December 2023. This commitment to quality standards provides customers with confidence in the product's suitability for intended use.

The scope of their certifications is broad, covering:

• API (Active Pharmaceutical Ingredients)
• Semi-finished cannabis products
• Finished cannabis products

Reliable, diversified global supply chain to over 15 countries

The value proposition includes the ability to reliably move product across borders. Clever Leaves Holdings Inc. has established a global footprint, successfully exporting to more than 15 countries. This network includes key regulated markets. The company's 2021 production quota from the Colombian government was substantial, authorizing them to manufacture up to approximately 59,000 kilograms of cannabis into dried flower derivatives, which at the time represented about 18% of the world's legal medical cannabis production quota for that year.

Here's a look at some of the markets they serve:

Region/Country	Product Focus
Germany	Medical Cannabis Imports
Australia	TGA Certified Products
Brazil	Cannabinoid Distribution
United Kingdom	Pharmaceutical Channel Supply
Czech Republic	Medical Cannabis Extracts

High-quality Active Pharmaceutical Ingredients (APIs) and finished flower

Clever Leaves Holdings Inc. focuses on producing both the raw, high-purity components and the final consumer-ready product. They produce cannabinoid active pharmaceutical ingredients (API) and finished products in both flower and extract form for their B2B clientele. This dual output capability allows them to serve different parts of the value chain, from pharmaceutical formulators needing isolates to distributors requiring dried flower.

Dual-segment offering (Cannabinoid and Non-Cannabinoid, pre-sale)

You aren't just buying cannabis; you are engaging with a company that has two distinct revenue drivers. The business operates through the Cannabinoid segment, which handles cultivation, extraction, and distribution of cannabis products internationally. The other stream is the Non-Cannabinoid segment, which formulates and sells nutraceuticals and other natural remedies, wellness products, and dietary supplements, primarily to retailers in the United States. To be fair, the Non-Cannabinoid segment historically generates the maximum revenue for the company. For instance, the trailing twelve-month revenue reported for 2023 was $17.42 million, with the latest reported annual revenue for 2024 reaching $17.7 million.

The segments break down like this:

• Cannabinoid: Cultivation, extraction, APIs, flower.
• Non-Cannabinoid: Nutraceuticals, wellness products, supplements.

The company's financial performance shows the challenge: 2023 saw revenue of $17.42 million against losses of -$17.90 million.

Finance: draft 13-week cash view by Friday.

Clever Leaves Holdings Inc. (CLVR) - Canvas Business Model: Customer Relationships

You're looking at how Clever Leaves Holdings Inc. manages its relationships with the entities buying its pharmaceutical-grade cannabis products, especially now that they've gone private. The strategy clearly pivots around high-touch service for regulated B2B buyers and cost-conscious execution for bulk sales.

Dedicated B2B account management for pharmaceutical clients

For pharmaceutical clients, the relationship is managed through dedicated B2B account management. This is crucial because you're dealing with Active Pharmaceutical Ingredients (APIs) and finished products requiring stringent quality control. Clever Leaves Holdings Inc. focuses its commercial efforts on key international markets, including Australia, Brazil, Germany, Israel, and the United Kingdom, as part of its post-delisting strategy. The company's operations in Colombia produce EU GMP cannabinoid APIs and finished products for this growing base of B2B customers globally. As of the end of 2023, cannabinoid sales, which feed these B2B relationships, had surged by 39% year-over-year, reaching $6.6 million of the total $17.4 million revenue for that year. This indicates the high value placed on these specific customer accounts.

Long-term, high-volume supply contracts with fixed terms

The foundation of the pharmaceutical client relationship is built on securing long-term, high-volume supply contracts. These agreements lock in demand for the company's output, providing revenue visibility. The process for securing these involves a multi-step validation: identifying a prospective customer, defining product specifications, securing country-specific regulatory approval, and finally, achieving repeat/regular purchase orders after an initial validation shipment. While specific 2025 contract values aren't public, the 2023 revenue of $17.42 million reflects the scale of these ongoing commitments.

Regulatory and technical consulting support for partners

Clever Leaves Holdings Inc. supports its partners by leveraging its regulatory expertise, which is a key value-add in this complex sector. The company holds multiple international certifications, including European Union Good Manufacturing Practices (EU GMP) Certification, a GMP Certification by Colombia National Food and Drug Surveillance Institute - Invima, and Good Agricultural and Collecting Practices (GACP) Certification. This deep compliance knowledge helps partners navigate import/export permits and product acceptance. The company's Chief Regulatory Officer is a key part of this relationship structure.

Direct, transactional sales for bulk dried flower exports

For bulk dried flower, the relationship model shifts to be more direct and transactional, focusing on leveraging low-cost production. The company aims to commercially launch high-THC flower produced in Colombia. Historically, Clever Leaves Holdings Inc. has executed significant flower transactions; for example, they exported 30 kg of high-THC cannabis flower from Portugal to a U.S. partner in October 2021. Furthermore, a past research initiative involved pledging up to 5 tons of cannabis flower at no cost to advance U.S. scientific research, showing a willingness to transact large volumes based on strategic need.

The following table summarizes the different customer engagement types and associated scale indicators:

Customer Relationship Type	Primary Product Focus	Key Metric/Scale Indicator	Geographic Focus (Post-2024 Strategy)
Dedicated B2B Account Management	APIs, Finished Pharmaceutical Products	Cannabinoid Revenue: $6.6 million (2023)	Germany, Brazil, Australia, Israel, UK
Long-Term Supply Contracts	EU GMP Certified Materials	Total Revenue: $17.4 million (2023)	Global B2B Network
Regulatory/Technical Support	All Products	Holding EU GMP, GACP Certifications	Partners requiring compliance pathways
Direct/Transactional Sales	Bulk Dried Flower	Historical Flower Export: 30 kg (Single Shipment)	Markets with high flower demand

Investor relations and public disclosure (voluntary delisting in 2024)

The relationship with public market investors fundamentally changed in 2024. Clever Leaves Holdings Inc. voluntarily delisted from NASDAQ around May 16, 2024, and subsequently filed a Form 15 to suspend reporting obligations under the Exchange Act, meaning no more mandatory Forms 10-K, 10-Q, and 8-K. This was done to reduce the significant operating expense and regulatory burden associated with public trading. The company's market capitalization as of December 4, 2025, stood at $526.00, a significant decrease from its prior public standing, reflecting the shift away from public market scrutiny. The company now communicates material information through its website and press releases, a different relationship dynamic than required by the SEC.

• Investor communication channels now include the company website (https://cleverleaves.com) and social media.
• The decision to delist was partly due to non-compliance with Nasdaq's listing requirements.
• The company aims to continue reducing operating expenses, having achieved a 26% reduction in General and Administrative expenses in Q4 2023.

Clever Leaves Holdings Inc. (CLVR) - Canvas Business Model: Channels

You're looking at how Clever Leaves Holdings Inc. gets its pharmaceutical-grade cannabinoid products out to the world, which is critical given their focus on international, regulated markets. The channel strategy heavily relies on certified partners and direct export from their primary production hub.

Direct B2B sales force targeting pharmaceutical and CPG companies

The core of the B2B approach involves direct engagement with pharmaceutical entities for Active Pharmaceutical Ingredients (APIs) and finished products. For instance, the company has a five-year agreement to supply EU-GMP-certified CBD extracts from Colombia to SOMAÍ Pharmaceuticals in Portugal. This direct supply channel is designed to feed European drug delivery systems. While specific 2025 revenue attribution to the direct sales force isn't public, the company's total trailing 12-month revenue as of December 31, 2023, stood at $17.42M.

International distribution partners and licensed importers

Clever Leaves Holdings Inc. uses established local entities to navigate complex regulatory landscapes. In Germany, Cansativa, a Frankfurt-based certified importer and distributor, handles sales and distribution of Clever Leaves' extracts and oral solutions. The company's investment in Cansativa accelerated its participation in that specific market. Historically, Clever Leaves has exported to over 15 countries, demonstrating a broad network of potential or existing distribution relationships.

The structure of these partnerships can be summarized:

Market/Partner Type	Known Partner Example (as of latest data)	Product Supplied	Facility Origin
European Biopharma	SOMAÍ Pharmaceuticals	EU-GMP-certified CBD extracts	Colombia
German Distributor	Cansativa	Extracts and oral solutions	Colombia
Australian Partner	Cannatrek	White label finished products (OS 20%CBD and OS 10%CBD)	Colombia (Historical context)

Direct export from Colombia and Portugal facilities

The primary export channel centers on the Colombian greenhouses, which span over 1.8 million square feet of fully built-out cultivation capacity. The extraction facility there was capable of extracting 104,400 kilograms of dried flower annually, with expansion underway to reach 324,000 kilograms per year. It is important to note that cultivation and manufacturing activities in Portugal ceased in full by the end of the first quarter of 2023, meaning all 2025 dry flower exports are solely from the Colombian facility. The company has secured significant production quotas, representing 50% of Colombia's total quota and approximately 18% of the world's legal medical cannabis production quota for 2021, setting the stage for export capacity.

Academic and research institution supply channels

This channel focuses on supplying material to advance scientific knowledge. In a notable 2021 initiative, Project Change Lives, Clever Leaves Holdings Inc. pledged up to USD $25,000,000 retail value of medical cannabis products to eligible U.S. organizations. This included offering up to 250,000 bottles of cannabis oil or approximately 5 tons of medical cannabis flower, provided at no cost to research partners.

Key research supply metrics:

• Pledged product value: Up to $25,000,000 (retail value).
• Product volume offered: Up to 250,000 bottles of oil.
• Product volume offered: Up to 5 tons of flower.
• Compliance standard: Pharmaceutical-grade cannabis.

Digital presence for corporate and investor communication

The digital channel supports corporate visibility and investor relations, though specific 2025 engagement metrics are not available. The company maintains its listing on the Nasdaq under ticker symbol CLVR (though trading has seen extreme volatility, with a market cap reported at $526.00 as of December 4, 2025). The digital presence is used to communicate operational milestones, such as receiving EU-GMP certification for its Colombian facilities, which is generally required to import into the European Union. The company also reports having nearly 300 full-time employees as of late 2024/early 2025 data points.

Clever Leaves Holdings Inc. (CLVR) - Canvas Business Model: Customer Segments

You're looking at the core buyers for Clever Leaves Holdings Inc. as of late 2025. The business model is heavily weighted toward B2B supply in the pharmaceutical and medical cannabis space, leveraging its Colombian cultivation and EU GMP certifications. Honestly, the biggest shift impacting this section recently was the divestiture of the other side of the business.

The company operates primarily through its Cannabinoid segment, which focuses on cultivation, extraction, and distribution of pharmaceutical-grade products. For context, the full-year 2024 revenue reached $17.7 million, building on the 2023 full-year cannabinoid revenue growth of 39%.

The customer base is segmented by the type of regulated product required:

• Global Pharmaceutical and Biotech Companies requiring Active Pharmaceutical Ingredients (API) and standardized extracts.
• International Medical Cannabis Distributors and Importers needing registered flower and extract products.
• Academic and Government Research Institutions requiring validated, traceable cannabis material.
• Nutraceutical and Wellness Brands, though this group is now largely historical following a major transaction.

The Non-Cannabinoid segment, which served mass and specialty retailers in the U.S. with wellness products and nutraceuticals, was sold off. Clever Leaves Holdings Inc. completed the sale of this herbal brands business on March 21, 2024, for a total consideration of $8.02 million, which included $7.02 million in cash paid at closing. So, that customer group is no longer a focus for the current structure.

The international reach is significant, with export shipments having reached over a dozen jurisdictions, including Germany, Brazil, the United Kingdom, and Australia. The focus remains on providing lower-cost, reliable supply to these partners.

Here's a breakdown of the primary B2B customer types within the core Cannabinoid segment:

Customer Segment Focus	Product Form Supplied	Geographic Sales Focus (Primary)	Key Requirement Met
Global Pharmaceutical and Biotech Companies	Active Pharmaceutical Ingredients (API), Oral Solutions, Standardized Extracts	Primarily outside of the U.S.	EU GMP Certification and Traceability
International Medical Cannabis Distributors and Importers	Cannabis Flowers (THC/CBD), Full Spectrum Extracts	Germany, Brazil, Australia, and others (over 15 countries served historically)	Reliable, Year-Round Supply and Product Registrations
Academic and Government Research Institutions	Validated Extracts, Specific Cultivar Material	Global (subject to local regulation)	Consistent Quality and Cultivar Registration (e.g., through Paradise Seeds collaboration)
CPG Companies (B2B Ingredient Supply)	Cannabidiol (CBD) Isolates	International Markets	Bulk Ingredient Supply for Downstream Formulation

The company's production locations in Colombia, which boast over 10 million square feet of licensed cultivation capacity, are key to serving these segments with environmentally sustainable, industrial-scale output. This capacity supports the consistent supply needed by major international importers and pharmaceutical partners.

Clever Leaves Holdings Inc. (CLVR) - Canvas Business Model: Cost Structure

You're looking at the cost side of Clever Leaves Holdings Inc. (CLVR)'s operations, which is heavily influenced by its strategic pivot to low-cost, high-quality production centered in Colombia. The structure clearly shows a trade-off between high initial compliance costs and low ongoing cultivation expenses.

High fixed costs for maintaining GMP-certified facilities and compliance are a given when you operate at a pharmaceutical standard. Clever Leaves Holdings Inc. maintains its EU GMP-certified extraction operation and cultivation facilities in Colombia, which span over 1.8 Million sq. ft. of fully built-out capacity. These certifications are not cheap to acquire or maintain, representing a significant fixed overhead necessary to access premium international markets like Germany and Australia.

The core advantage, however, lies in the low variable cultivation costs due to Colombian climate advantage. The equatorial location provides a consistent 12 hours of sunlight year-round, reducing the need for costly light supplementation and minimizing pesticide use. This natural advantage allowed Clever Leaves Holdings Inc. to produce cannabis at a reported cost as low as $0.20 per gram in high volume, which was roughly 1/10 the cost of many leading Canadian producers at the time of that comparison. To be fair, the all-in cost per gram of dry flower was reported at $0.75 in FY 2023, up from $0.36 in FY 2022, a change management attributed to reduced agricultural output early in 2023 and quality improvements.

The company has been aggressively tackling overhead through significant operating expense reduction. Reflecting these optimization efforts, Clever Leaves Holdings Inc. drove year-over-year General and Administrative (G&A) expense reductions of 24% for the full year 2023. For the fourth quarter of 2023 specifically, the G&A cut was 26% year-over-year. Total Operating Expenses improved significantly, moving from $54.14 Million in FY 2022 down to $22.15 Million in Q4 2023. This focus on capital efficiency was further supported by divestitures, such as the sale of Portuguese farm assets for $1.5 Million and the sale of the Non-Cannabinoid Herbal Brands Business for $8.02 Million.

When we look at the Costs of Goods Sold (COGS) and Gross Margin, the picture is clearer when using the adjusted figures, which strip out one-time inventory provisions. The outline mentioned a 45% gross margin target for FY 2024; the company achieved an Adjusted Gross Margin of 45.4% in FY 2023. The latest reported margin figure available, as of late 2025 context, is 37.64%. Here's a look at the core COGS components from the last full financial report (FY 2023):

Metric (USD Millions)	FY 2023	FY 2022
Total Revenue	$17.42	$16.41
Cost of Revenue (COGS)	$10.86	$9.19
Gross Profit (Reported)	$6.56	$7.22
Adjusted Gross Margin	45.4%	56.3%

Finally, International regulatory and legal compliance expenses are embedded within both fixed costs and operating expenses. Clever Leaves Holdings Inc. is structured to supply pharmaceutical-grade products to over 15 countries globally, including key markets like Australia, Brazil, and Germany. Successfully navigating the distinct import and quality regulations in each jurisdiction requires dedicated legal and regulatory teams, which contributes to the sustained Selling, General & Admin (SG&A) spend, which totaled $20.03 Million in FY 2023.

You should review the cash flow statement to see how the divestiture proceeds of $8.02 Million from the Herbal Brands sale are being allocated against ongoing compliance and operational burn rate. Finance: draft 13-week cash view by Friday.

Clever Leaves Holdings Inc. (CLVR) - Canvas Business Model: Revenue Streams

You're looking at how Clever Leaves Holdings Inc. actually brings in the money now that the focus is purely on high-quality, EU-GMP certified cannabis for global pharmaceutical markets. The numbers tell a clear story of strategic divestiture and focus on the core cannabinoid business.

The Total annual revenue for the fiscal year 2024 was reported to be approximately $17.7 million.

The shift away from the diversified model is concrete, marked by the divestiture of the non-core business:

• Sales from the Non-Cannabinoid segment (prior to March 2024 sale): The sale of the Herbal Brands business was completed on March 21, 2024, for a total consideration of $8.02 million, which included $7.02 million in cash paid at closing.

The remaining, core revenue streams are entirely within the cannabinoid segment, which includes both API/extracts and dried flower exports. While the precise 2024 breakdown isn't public, the 2023 figures show the relative weight before the sale:

Revenue Stream Type (Based on 2023 Data)	Reported Annual Revenue (FY 2023)
Cannabinoid Revenue (API, Extracts, Flower)	$6.6 million
Non-Cannabinoid Revenue (Sold in 2024)	$10.9 million
Total Annual Revenue (FY 2023)	$17.4 million

The primary focus of the current revenue generation is:

• Sales of Cannabinoid Active Pharmaceutical Ingredients (API) and extracts: These are produced in Colombia under EU-GMP standards and sold to B2B customers globally.
• Revenue from bulk EU-GMP certified dried cannabis flower exports: Shipments are supported by certifications including EU GMP, Australian GMP, and ANVISA GMP, targeting markets like Australia, Germany, and Israel.

The entire structure of the cannabinoid business is built around securing long-term commercial relationships, which is the mechanism for future revenue stability. The commercial strategy involves a multi-step process to convert initial shipments into recurring sales:

• Revenue from long-term B2B supply agreements: The business model is focused on partnering with leading and emerging cannabis and pharmaceutical businesses by providing them with lower cost product and reliable supply.
• The pathway to securing this revenue involves: Identify Prospective Customer, Develop & Country-Specific Regulatory Path Determined, Quality Systems Audit, New Supply Agreement Secured, Initial Pathfinder Shipment, Validation of Product Quality, Country-Specific Regulatory Approval, Apply for & Obtain Export & Import Permits, 1st Commercial Shipment, Receive Market Feedback, Achieve Acceptance, and finally, Expect to Achieve Repeat/Regular Purchase Orders.

Finance: draft 13-week cash view by Friday.